ClinicalTrials.gg
CompletedNCT03926130VIVID-1Updated Dec 27, 2024Results posted

A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

A Phase 3 interventional study of Mirikizumab and Mirikizumab in Crohn's Disease, sponsored by Eli Lilly and Company. Completed at 580 sites in 34 countries. Open to participants aged 15 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-12-27.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,158
Allocation
Randomized
Ages
15 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing mirikizumab in Crohn Disease — 7 open to participants now, 8 under way, 3 of them phase 3. mirikizumab · Crohn Disease.

Enrollment
Largest of 10
1,158 · median 150
Started
2019
the only one that year
Phase 3
4 of 10
2 open now
Registered
2nd of 10
by date
Lead sponsor
5 of 10
Eli Lilly and Company

Among the 10 studies testing mirikizumab in Crohn Disease, this one has the largest enrollment, is the only one that started in 2019, is one of 4 in phase 3, and was the 2nd registered.

Crohn Disease

1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

7 of the 10 studies testing mirikizumab in Crohn Disease are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About mirikizumab

mirikizumab: first FDA approval 2023 (OMVOH), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.

This study: 15 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing mirikizumab in Crohn Disease, or all of them as a file.
02

Study summary

The reason for this study is to see if the study drug mirikizumab is safe and effective in participants with moderately to severely active Crohn's disease.

03

Conditions studied

  • Crohn's Disease

Browse trials for

04

Who can participate

Ages eligible
15 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of CD for at least 3 months prior to baseline
  • Confirmed diagnosis of moderate to severe CD as assessed by SF, AP score, and SES-CD
  • Demonstrated intolerance, loss of response or inadequate response to conventional or to biologic therapy for CD
  • If female, subject must meet the recommendations

Exclusion criteria

Exclusion Criteria:

  • Have a current diagnosis of ulcerative colitis, inflammatory bowel disease-unclassified (IBD-U) (formerly known as indeterminate colitis) or short bowel syndrome
  • Currently have or are suspected to have an abscess. Recent cutaneous and perianal abscesses are not exclusionary if drained, adequately treated and resolved at least 3 weeks prior to baseline or 8 weeks prior to baseline for intra-abdominal abscesses, provided that there is no anticipated need for any further surgery
  • Have a stoma, ileoanal pouch or ostomy
  • Have had a bowel resection within 6 months, or any kind of intra-abdominal or extra abdominal surgery within 3 months of baseline
  • Have ever received any monoclonal antibodies binding IL-23
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
1,158 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants received Placebo intravenously (IV) or subcutaneously (SC) every 4 weeks (Q4W). Any participant in the placebo arm who was considered a non-responder at Week 12 received 900 mg Mirikizumab IV Q4W for 3 doses, then 300 mg SC Q4W for the remainder of the study. Nonresponse is defined as failing to achieve at least a 30% decrease in stool frequency (SF) and/or abdominal pain (AP) and be no worse than baseline.

    Drug: Placebo

  • Experimental
    300 mg Mirikizumab

    Participants received 900 milligrams (mg) Mirikizumab IV Q4W for 3 doses, then 300 mg SC Q4W

    Drug: Mirikizumab

  • Active comparator
    90 mg Ustekinumab

    Participants received 6 mg/kg Ustekinumab IV for one dose, then 90 mg SC every 8 weeks (Q8W)

    Drug: Ustekinumab

  • Experimental
    300 mg Mirikizumab (Adolescents)

    Participants received open label 900 mg Mirikizumab IV for 3 doses, then 300 mg SC Q4W

    Drug: Mirikizumab

Interventions

  • Administered IV

    Also known as: LY3074828

  • Administered SC

    Also known as: LY3074828

  • Administered IV

  • Administered SC

  • DrugPlacebo

    Administered IV

  • DrugPlacebo

    Administered SC

06

What researchers measure

Primary outcomes

  1. Percentage of Adult Participants Achieving Clinical Response at Week 12 and Endoscopic Response at Week 52 (Placebo and Mirikizumab)

    Clinical response by patient reported outcome (PRO) defined as ≥30% decrease in stool frequency (SF) and/or abdominal pain (AP) \& neither score worse than baseline. SF (number of liquid or very soft stools) as per Bristol Stool Scale Category 6 or 7 and AP (4-point scale: 0=none, 1=mild, 2=moderate, 3=severe). Endoscopic response defined as ≥50% reduction from baseline in total Simple Endoscopic Score for Crohn's Disease (SES-CD) score. SES-CD evaluates 4 variables assessed in 5 bowel segments, each scored from 0-3: presence \& size of ulcers (none=0; diameter 0.1-0.5 cm=1; 0.5-2 cm=2; \>2 cm=3); extent of ulcerated surface (none=0; \<10%=1; 10% to 30%=2; \>30%=3); extent of affected surface (none=0; \<50%=1; 50% to 75%=2; \>75%=3); presence \& type of narrowing (none=0; single, can be passed=1; multiple, can be passed=2; cannot be passed=3). Total is sum of all scores across all bowel segments. Scores range from 0 to 56, with higher scores indicating more severe disease.

    Time frame: Week 12 to Week 52

  2. Percentage of Adult Participants Achieving Clinical Response at Week 12 and Clinical Remission at Week 52 (Placebo and Mirikizumab)

    Clinical response by PRO defined as ≥ 30% decrease in SF and/or AP and neither score worse than baseline. SF (number of liquid or very soft stools) as per Bristol Stool Scale Category 6 or 7 and AP (4-point scale: 0=none, 1=mild, 2=moderate, 3=severe). Clinical remission defined as Crohn's Disease Activity Index (CDAI) total score \<150. The CDAI is an 8-item disease activity measure comprised of a composite of 3 patient-reported items: AP (4-point scale: 0=none, 1=mild, 2=moderate, 3=severe); SF (number of liquid or very soft stools) as per Bristol Stool Scale Category 6 or 7; and general well-being (0=generally well, 1=slightly under par, 2=poor, 3=very poor, 4=terrible), and 5 physician-reported/laboratory items (physical signs and a laboratory parameter \[hematocrit\]).. Total score range of 0 to 600 points.

    Time frame: Week 12 to Week 52

Secondary outcomes

  1. Percentage of Adult Participants Achieving Endoscopic Response at Week 12 (Placebo and Mirikizumab)

    Endoscopic Response defined as ≥50% reduction from baseline in SES-CD total score. SES-CD evaluates 4 variables assessed in 5 bowel segments, each scored from 0-3: presence \& size of ulcers (none = 0; diameter 0.1-0.5 cm = 1; 0.5-2 cm = 2; \>2 cm = 3); extent of ulcerated surface (none = 0; \<10% = 1; 10% to 30% = 2; \>30% = 3); extent of affected surface (none = 0; \<50% = 1; 50% to 75% = 2; \>75% = 3); presence \& type of narrowing (none = 0; single, can be passed = 1; multiple, can be passed = 2; cannot be passed = 3). Total is sum of all scores across all bowel segments. Scores range from 0 to 56, with higher scores indicating more severe disease.

    Time frame: Week 12

  2. Percentage of Adult Participants Achieving Endoscopic Response at Week 52

    Endoscopic Response defined as ≥50% reduction from baseline in SES-CD total score. SES-CD evaluates 4 variables assessed in 5 bowel segments, each scored from 0-3: presence \& size of ulcers (none = 0; diameter 0.1-0.5 cm = 1; 0.5-2 cm = 2; \>2 cm = 3); extent of ulcerated surface (none = 0; \<10% = 1; 10% to 30% = 2; \>30% = 3); extent of affected surface (none = 0; \<50% = 1; 50% to 75% = 2; \>75% = 3); presence \& type of narrowing (none = 0; single, can be passed = 1; multiple, can be passed = 2; cannot be passed = 3). Total is sum of all scores across all bowel segments. Scores range from 0 to 56, with higher scores indicating more severe disease.

    Time frame: Week 52

  3. Percentage of Adult Participants Achieving Clinical Remission at Week 12 (Placebo and Mirikizumab)

    Clinical remission defined as CDAI total score \<150. The CDAI is an 8- item disease activity measure comprised of a composite of 3 patient-reported items: AP (4-point scale: 0=none, 1=mild, 2=moderate, 3=severe); SF (number of liquid or very soft stools) as per Bristol Stool Scale Category 6 or 7; and general well-being (0=generally well, 1=slightly under par, 2=poor, 3=very poor, 4=terrible), and 5 physician-reported/laboratory items (physical signs and a laboratory parameter \[hematocrit\]). Total score range of 0 to 600 points.

    Time frame: Week 12

  4. Percentage of Adult Participants Achieving Clinical Remission at Week 52

    Clinical remission defined as CDAI total score \<150. The CDAI is an 8- item disease activity measure comprised of a composite of 3 patient-reported items: AP (4-point scale: 0=none, 1=mild, 2=moderate, 3=severe); SF (number of liquid or very soft stools) as per Bristol Stool Scale Category 6 or 7; and general well-being (0=generally well, 1=slightly under par, 2=poor, 3=very poor, 4=terrible), and 5 physician-reported/laboratory items (physical signs and a laboratory parameter \[hematocrit\]). Total score range of 0 to 600 points.

    Time frame: Week 52

  5. Percentage of Adult Participants Achieving Endoscopic Remission at Week 12 (Placebo and Mirikizumab)

    Endoscopic remission is defined as SES-CD Total Score ≤4 and at least a 2-point reduction from baseline and no subscore \>1. SES-CD evaluates 4 endoscopic variables in 5 bowel segments and each of the 20 individual variables is scored from 0-3: presence \& size of ulcers (none = 0; diameter 0.1-0.5 cm = 1; 0.5-2 cm = 2; \>2 cm = 3); extent of ulcerated surface (none = 0; \<10% = 1; 10% to 30% = 2; \>30% = 3); extent of affected surface (none = 0; \<50% = 1; 50% to 75% = 2; \>75% = 3); presence \& type of narrowing (none = 0; single, can be passed = 1; multiple, can be passed = 2; cannot be passed =3). Total is sum of all scores across all bowel segments. Scores range from 0 to 56, with higher scores indicating more severe disease. No subscore \>1 is defined as no segmental subscore (sum of the 4 individual variable scores for each of the 5 bowel segments) \>1.

    Time frame: Week 12

  6. Change From Baseline in Urgency Numeric Rating Scale (NRS) at Week 12 in Adult Participants (Placebo and Mirikizumab)

    The Urgency NRS is a single patient-reported item that measures the severity for the urgency (sudden or immediate need) to have a bowel movement in the past 24 hours using an 11-point NRS ranging from 0 (no urgency) to 10 (worst possible urgency).

    Time frame: Baseline, Week 12

  7. Change From Baseline in Urgency NRS at Week 52 in Adult Participants (Placebo and Mirikizumab)

    The Urgency NRS is a single patient-reported item that measures the severity for the urgency (sudden or immediate need) to have a bowel movement in the past 24 hours using an 11-point NRS ranging from 0 (no urgency) to 10 (worst possible urgency).

    Time frame: Baseline, Week 52

  8. Percentage of Adult Participants Achieving Clinical Response at Week 12 and Clinical Remission by PRO at Week 52 (Placebo and Mirikizumab)

    Clinical Response by PRO defined as ≥30% decrease in SF and/or AP \& neither score worse than baseline. SF (number of liquid or very soft stools) as per Bristol Stool Scale Category 6 or 7 and AP (4-point scale: 0=none, 1=mild, 2=moderate, 3=severe). Clinical Remission by PRO defined as SF≤3 and not worse than baseline (as per Bristol Stool Scale Category 6 or 7) and AP ≤1 and no worse than baseline.

    Time frame: Week 12 to Week 52

  9. Percentage of Adult Participants Achieving Clinical Response at Week 12 and Endoscopic Remission at Week 52 (Placebo and Mirikizumab)

    Clinical Response by PRO defined as ≥30% decrease in SF and/or AP \& neither score worse than baseline. SF (number of liquid or very soft stools) per Bristol Stool Scale Category 6 or 7 \& AP (4-point scale:0=none,1=mild,2=moderate,3=severe). Endoscopic remission=SES-CD Total Score ≤4 \& at least 2-point reduction from baseline \& no subscore \>1.SES-CD evaluates 4 endoscopic variables in 5 bowel segments \& each of 20 individual variables scored 0-3: presence \& size of ulcers (none=0;diameter 0.1-0.5 cm=1;0.5-2 cm=2;\>2 cm=3);extent of ulcerated surface (none=0;\<10%=1;10% to 30%=2;\>30%=3);extent of affected surface (none=0;\<50%=1;50% to 75%=2;\>75%=3);presence \& type of narrowing (none=0;single,can be passed=1;multiple,can be passed=2;cannot be passed=3). Total is sum of all scores across all bowel segments. Scores range from 0 to 56;higher scores indicating more severe disease. No subscore \>1=no segmental subscore (sum of the 4 individual variable scores for each of the 5 bowel segments) \>1

    Time frame: Week 12 to Week 52

  10. Percentage of Adult Participants Achieving Clinical Response at Week 12 and Corticosteroid-free Clinical Remission at Week 52 (Placebo and Mirikizumab)

    Clinical response by PRO defined as ≥30% decrease in SF and/or AP and neither score worse than baseline. SF (number of liquid or very soft stools) as per Bristol Stool Scale Category 6 or 7 and AP (4-point scale: 0=none, 1=mild, 2=moderate, 3=severe). Clinical remission defined as CDAI total score \<150. The CDAI is an 8- item disease activity measure comprised of a composite of 3 patient-reported items: AP (4-point scale: 0=none, 1=mild, 2=moderate, 3=severe); SF (number of liquid or very soft stools) as per Bristol Stool Scale Category 6 or 7; and general well-being (0=generally well, 1=slightly under par, 2=poor, 3=very poor, 4=terrible), and 5 physician-reported/laboratory items (physical signs and a laboratory parameter \[hematocrit\]). Total score range of 0 to 600 points. Corticosteroid-free clinical remission by CDAI is defined as achieving clinical remission by CDAI at Week 52 and being corticosteroid free from Week 40 to Week 52.

    Time frame: Week 12 to Week 52

  11. Change From Baseline in C-Reactive Protein (CRP) at Week 52 in Adult Participants (Placebo and Mirikizumab)

    Change from baseline in CRP

    Time frame: Baseline, Week 52

  12. Change From Baseline in Fecal Calprotectin at Week 52 in Adult Participants (Placebo and Mirikizumab)

    Change from baseline in Fecal Calprotectin

    Time frame: Baseline, Week 52

  13. Percentage of Adult Participants Achieving Clinical Response at Week 12 and Resolution of Baseline Extraintestinal Manifestations (EIMs) at Week 52 (Placebo and Mirikizumab)

    Clinical response by PRO defined as ≥30% decrease in SF and/or AP and neither score worse than baseline. SF (number of liquid or very soft stools) as per Bristol Stool Scale Category 6 or 7 and AP (4-point scale: 0=none, 1=mild, 2=moderate, 3=severe).

    Time frame: Week 12 to Week 52

  14. Percentage of Adult Participants Achieving Clinical Response at Week 12 and ≥50% Reduction in Number of Draining Cutaneous Fistulae at Week 52 in Participants With Draining Cutaneous Fistulae at Baseline (Placebo and Mirikizumab)

    Clinical response by PRO defined as ≥ 30% decrease in SF and/or AP and neither score worse than baseline. SF (number of liquid or very soft stools) as per Bristol Stool Scale Category 6 or 7 and AP (4-point scale: 0=none, 1=mild, 2=moderate, 3=severe).

    Time frame: Week 12 to Week 52

  15. Change From Baseline in Health Related Quality of Life at Week 52 in Adult Participants: Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score (Placebo and Mirikizumab)

    The IBDQ is a 32-item patient completed questionnaire that measures 4 aspects of patients' lives: symptoms directly related to the primary bowel disturbance, systemic symptoms, emotional function, and social function. Responses are graded on a 7-point Likert scale in which 7 denotes "not a problem at all" and 1 denotes "a very severe problem." IBDQ total score is calculated as the sum of all questions. Scores range from 32 to 224; a higher score indicates a better quality of life.

    Time frame: Baseline, Week 52

  16. Adult Population Pharmacokinetics (PopPK): Area Under the Concentration Time Curve (AUC) of Mirikizumab

    PopPK: AUC of Mirikizumab

    Time frame: 900 mg Mirikizumab: Week 4: Predose; Week 4, Day 1: Postdose; Week 8, 12: Predose 300 mg Mirikizumab: Week 16, 24, 36: Predose; Week 52

07

Results

Posted Dec 27, 2024
Limitations and caveats
After enrolling 6 participants, sponsor elected to stop enrollment of adolescents in study AMAM and enroll pediatric participants in a separate, pediatric study. The 6 enrolled participants were allowed to continue treatment and finish the study.

Participant flow

Participant flow — Overall Study
MilestonePlaceboMirikizumabUstekinumabMirikizumab (Adolescents)
Started2126313096
Received at least one dose of study drug2116303096
Placebo non-responder at week 1285000
Completed1595612714
Not completed5370382
Withdrew: Adverse event91120
Withdrew: Death2010
Withdrew: Lack of efficacy141171
Withdrew: Lost to follow-up0710
Withdrew: As reported by investigator2660
Withdrew: Physician decision3210
Withdrew: Pregnancy2210
Withdrew: Withdrawal by subject2028181
Withdrew: Non-compliance1100
Withdrew: Disposition not captured0210

Outcome measures

PrimaryPercentage of Adult Participants Achieving Clinical Response at Week 12 and Endoscopic Response at Week 52 (Placebo and Mirikizumab)

Clinical response by patient reported outcome (PRO) defined as ≥30% decrease in stool frequency (SF) and/or abdominal pain (AP) \& neither score worse than baseline. SF (number of liquid or very soft stools) as per Bristol Stool Scale Category 6 or 7 and AP (4-point scale: 0=none, 1=mild, 2=moderate, 3=severe). Endoscopic response defined as ≥50% reduction from baseline in total Simple Endoscopic Score for Crohn's Disease (SES-CD) score. SES-CD evaluates 4 variables assessed in 5 bowel segments, each scored from 0-3: presence \& size of ulcers (none=0; diameter 0.1-0.5 cm=1; 0.5-2 cm=2; \>2 cm=3); extent of ulcerated surface (none=0; \<10%=1; 10% to 30%=2; \>30%=3); extent of affected surface (none=0; \<50%=1; 50% to 75%=2; \>75%=3); presence \& type of narrowing (none=0; single, can be passed=1; multiple, can be passed=2; cannot be passed=3). Total is sum of all scores across all bowel segments. Scores range from 0 to 56, with higher scores indicating more severe disease.

Time frame:
Week 12 to Week 52
Reported as:
Mean · percentage of participants
Percentage of Adult Participants Achieving Clinical Response at Week 12 and Endoscopic Response at Week 52 (Placebo and Mirikizumab)
percentage of participantsPlaceboMirikizumab
Percentage of Adult Participants Achieving Clinical Response at Week 12 and Endoscopic Response at Week 52 (Placebo and Mirikizumab)9.0 (5.1 to 13.0)38.0 (34.0 to 42.0)
Statistical analysis
  • Placebo vs Mirikizumab · Cochran-Mantel-Haenszel · p = <0.000001 · Risk difference (rd): 28.7 · 95% CI 23.0 to 34.4
PrimaryPercentage of Adult Participants Achieving Clinical Response at Week 12 and Clinical Remission at Week 52 (Placebo and Mirikizumab)

Clinical response by PRO defined as ≥ 30% decrease in SF and/or AP and neither score worse than baseline. SF (number of liquid or very soft stools) as per Bristol Stool Scale Category 6 or 7 and AP (4-point scale: 0=none, 1=mild, 2=moderate, 3=severe). Clinical remission defined as Crohn's Disease Activity Index (CDAI) total score \<150. The CDAI is an 8-item disease activity measure comprised of a composite of 3 patient-reported items: AP (4-point scale: 0=none, 1=mild, 2=moderate, 3=severe); SF (number of liquid or very soft stools) as per Bristol Stool Scale Category 6 or 7; and general well-being (0=generally well, 1=slightly under par, 2=poor, 3=very poor, 4=terrible), and 5 physician-reported/laboratory items (physical signs and a laboratory parameter \[hematocrit\]).. Total score range of 0 to 600 points.

Time frame:
Week 12 to Week 52
Reported as:
Mean · percentage of participants
Percentage of Adult Participants Achieving Clinical Response at Week 12 and Clinical Remission at Week 52 (Placebo and Mirikizumab)
percentage of participantsPlaceboMirikizumab
Percentage of Adult Participants Achieving Clinical Response at Week 12 and Clinical Remission at Week 52 (Placebo and Mirikizumab)19.6 (14.1 to 25.1)45.4 (41.4 to 49.5)
Statistical analysis
  • Placebo vs Mirikizumab · Cochran-Mantel-Haenszel · p = <0.000001 · Risk difference (rd): 25.8 · 95% CI 18.8 to 32.7
SecondaryPercentage of Adult Participants Achieving Endoscopic Response at Week 12 (Placebo and Mirikizumab)

Endoscopic Response defined as ≥50% reduction from baseline in SES-CD total score. SES-CD evaluates 4 variables assessed in 5 bowel segments, each scored from 0-3: presence \& size of ulcers (none = 0; diameter 0.1-0.5 cm = 1; 0.5-2 cm = 2; \>2 cm = 3); extent of ulcerated surface (none = 0; \<10% = 1; 10% to 30% = 2; \>30% = 3); extent of affected surface (none = 0; \<50% = 1; 50% to 75% = 2; \>75% = 3); presence \& type of narrowing (none = 0; single, can be passed = 1; multiple, can be passed = 2; cannot be passed = 3). Total is sum of all scores across all bowel segments. Scores range from 0 to 56, with higher scores indicating more severe disease.

Time frame:
Week 12
Reported as:
Mean · percentage of participants
Percentage of Adult Participants Achieving Endoscopic Response at Week 12 (Placebo and Mirikizumab)
percentage of participantsPlaceboMirikizumab
Percentage of Adult Participants Achieving Endoscopic Response at Week 12 (Placebo and Mirikizumab)12.6 (8.0 to 17.2)32.5 (28.7 to 36.3)
Statistical analysis
  • Placebo vs Mirikizumab · Cochran-Mantel-Haenszel · p = <0.000001 · Risk difference (rd): 19.7 · 95% CI 13.7 to 25.6
SecondaryPercentage of Adult Participants Achieving Endoscopic Response at Week 52

Endoscopic Response defined as ≥50% reduction from baseline in SES-CD total score. SES-CD evaluates 4 variables assessed in 5 bowel segments, each scored from 0-3: presence \& size of ulcers (none = 0; diameter 0.1-0.5 cm = 1; 0.5-2 cm = 2; \>2 cm = 3); extent of ulcerated surface (none = 0; \<10% = 1; 10% to 30% = 2; \>30% = 3); extent of affected surface (none = 0; \<50% = 1; 50% to 75% = 2; \>75% = 3); presence \& type of narrowing (none = 0; single, can be passed = 1; multiple, can be passed = 2; cannot be passed = 3). Total is sum of all scores across all bowel segments. Scores range from 0 to 56, with higher scores indicating more severe disease.

Time frame:
Week 52
Reported as:
Mean · percentage of participants
Percentage of Adult Participants Achieving Endoscopic Response at Week 52
percentage of participantsPlaceboMirikizumabUstekinumab
Percentage of Adult Participants Achieving Endoscopic Response at Week 529 (5.1 to 13.0)48.4 (44.3 to 52.4)46.3 (40.6 to 52.1)
Statistical analysis
  • Placebo vs Mirikizumab · Cochran-Mantel-Haenszel · p = <0.000001 · Risk difference (rd): 39.1 · 95% CI 33.4 to 44.8
  • Mirikizumab vs Ustekinumab · Cochran-Mantel-Haenszel · p = 0.513623 · Risk difference (rd): 2.3 · 95% CI -4.7 to 9.3
SecondaryPercentage of Adult Participants Achieving Clinical Remission at Week 12 (Placebo and Mirikizumab)

Clinical remission defined as CDAI total score \<150. The CDAI is an 8- item disease activity measure comprised of a composite of 3 patient-reported items: AP (4-point scale: 0=none, 1=mild, 2=moderate, 3=severe); SF (number of liquid or very soft stools) as per Bristol Stool Scale Category 6 or 7; and general well-being (0=generally well, 1=slightly under par, 2=poor, 3=very poor, 4=terrible), and 5 physician-reported/laboratory items (physical signs and a laboratory parameter \[hematocrit\]). Total score range of 0 to 600 points.

Time frame:
Week 12
Reported as:
Mean · percentage of participants
Percentage of Adult Participants Achieving Clinical Remission at Week 12 (Placebo and Mirikizumab)
percentage of participantsPlaceboMirikizumab
Percentage of Adult Participants Achieving Clinical Remission at Week 12 (Placebo and Mirikizumab)25.1 (19.1 to 31.2)37.7 (33.7 to 41.6)
Statistical analysis
  • Placebo vs Mirikizumab · Cochran-Mantel-Haenszel · p = 0.001431 · Risk difference (rd): 12.4 · 95% CI 5.3 to 19.6
SecondaryPercentage of Adult Participants Achieving Clinical Remission at Week 52

Clinical remission defined as CDAI total score \<150. The CDAI is an 8- item disease activity measure comprised of a composite of 3 patient-reported items: AP (4-point scale: 0=none, 1=mild, 2=moderate, 3=severe); SF (number of liquid or very soft stools) as per Bristol Stool Scale Category 6 or 7; and general well-being (0=generally well, 1=slightly under par, 2=poor, 3=very poor, 4=terrible), and 5 physician-reported/laboratory items (physical signs and a laboratory parameter \[hematocrit\]). Total score range of 0 to 600 points.

Time frame:
Week 52
Reported as:
Mean · percentage of participants
Percentage of Adult Participants Achieving Clinical Remission at Week 52
percentage of participantsPlaceboMirikizumabUstekinumab
Percentage of Adult Participants Achieving Clinical Remission at Week 5219.6 (14.1 to 25.1)54.1 (50.0 to 58.1)48.4 (42.7 to 54.2)
Statistical analysis
  • Placebo vs Mirikizumab · Cochran-Mantel-Haenszel · p = <0.000001 · Risk difference (rd): 34.6 · 95% CI 27.7 to 41.4
  • Mirikizumab vs Ustekinumab · Z test · p = <0.0001 · Risk difference (rd): 5.7 · 95% CI -1.4 to 12.8
SecondaryPercentage of Adult Participants Achieving Endoscopic Remission at Week 12 (Placebo and Mirikizumab)

Endoscopic remission is defined as SES-CD Total Score ≤4 and at least a 2-point reduction from baseline and no subscore \>1. SES-CD evaluates 4 endoscopic variables in 5 bowel segments and each of the 20 individual variables is scored from 0-3: presence \& size of ulcers (none = 0; diameter 0.1-0.5 cm = 1; 0.5-2 cm = 2; \>2 cm = 3); extent of ulcerated surface (none = 0; \<10% = 1; 10% to 30% = 2; \>30% = 3); extent of affected surface (none = 0; \<50% = 1; 50% to 75% = 2; \>75% = 3); presence \& type of narrowing (none = 0; single, can be passed = 1; multiple, can be passed = 2; cannot be passed =3). Total is sum of all scores across all bowel segments. Scores range from 0 to 56, with higher scores indicating more severe disease. No subscore \>1 is defined as no segmental subscore (sum of the 4 individual variable scores for each of the 5 bowel segments) \>1.

Time frame:
Week 12
Reported as:
Mean · percentage of participants
Percentage of Adult Participants Achieving Endoscopic Remission at Week 12 (Placebo and Mirikizumab)
percentage of participantsPlaceboMirikizumab
Percentage of Adult Participants Achieving Endoscopic Remission at Week 12 (Placebo and Mirikizumab)4.0 (1.3 to 6.7)10.9 (8.3 to 13.4)
Statistical analysis
  • Placebo vs Mirikizumab · Cochran-Mantel-Haenszel · p = 0.003414 · Risk difference (rd): 6.8 · 95% CI 3.2 to 10.5
SecondaryChange From Baseline in Urgency Numeric Rating Scale (NRS) at Week 12 in Adult Participants (Placebo and Mirikizumab)

The Urgency NRS is a single patient-reported item that measures the severity for the urgency (sudden or immediate need) to have a bowel movement in the past 24 hours using an 11-point NRS ranging from 0 (no urgency) to 10 (worst possible urgency).

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · score on a scale
Change From Baseline in Urgency Numeric Rating Scale (NRS) at Week 12 in Adult Participants (Placebo and Mirikizumab)
score on a scalePlaceboMirikizumab
Change From Baseline in Urgency Numeric Rating Scale (NRS) at Week 12 in Adult Participants (Placebo and Mirikizumab)-1.58 ± 0.168-2.44 ± 0.099
Statistical analysis
  • Placebo vs Mirikizumab · ANCOVA · p = 0.000011 · Lsmean difference (net): -0.86 · 95% CI -1.24 to -0.48
SecondaryChange From Baseline in Urgency NRS at Week 52 in Adult Participants (Placebo and Mirikizumab)

The Urgency NRS is a single patient-reported item that measures the severity for the urgency (sudden or immediate need) to have a bowel movement in the past 24 hours using an 11-point NRS ranging from 0 (no urgency) to 10 (worst possible urgency).

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · score on a scale
Change From Baseline in Urgency NRS at Week 52 in Adult Participants (Placebo and Mirikizumab)
score on a scalePlaceboMirikizumab
Change From Baseline in Urgency NRS at Week 52 in Adult Participants (Placebo and Mirikizumab)-1.23 ± 0.180-3.24 ± 0.106
Statistical analysis
  • Placebo vs Mirikizumab · ANCOVA · p = <0.000001 · Lsmean difference (net): -2.01 · 95% CI -2.42 to -1.60
SecondaryPercentage of Adult Participants Achieving Clinical Response at Week 12 and Clinical Remission by PRO at Week 52 (Placebo and Mirikizumab)

Clinical Response by PRO defined as ≥30% decrease in SF and/or AP \& neither score worse than baseline. SF (number of liquid or very soft stools) as per Bristol Stool Scale Category 6 or 7 and AP (4-point scale: 0=none, 1=mild, 2=moderate, 3=severe). Clinical Remission by PRO defined as SF≤3 and not worse than baseline (as per Bristol Stool Scale Category 6 or 7) and AP ≤1 and no worse than baseline.

Time frame:
Week 12 to Week 52
Reported as:
Mean · percentage of participants
Percentage of Adult Participants Achieving Clinical Response at Week 12 and Clinical Remission by PRO at Week 52 (Placebo and Mirikizumab)
percentage of participantsPlaceboMirikizumab
Percentage of Adult Participants Achieving Clinical Response at Week 12 and Clinical Remission by PRO at Week 52 (Placebo and Mirikizumab)19.6 (14.1 to 25.1)45.4 (41.4 to 49.5)
Statistical analysis
  • Placebo vs Mirikizumab · Cochran-Mantel-Haenszel · p = <0.000001 · Risk difference (rd): 25.7 · 95% CI 18.9 to 32.6
SecondaryPercentage of Adult Participants Achieving Clinical Response at Week 12 and Endoscopic Remission at Week 52 (Placebo and Mirikizumab)

Clinical Response by PRO defined as ≥30% decrease in SF and/or AP \& neither score worse than baseline. SF (number of liquid or very soft stools) per Bristol Stool Scale Category 6 or 7 \& AP (4-point scale:0=none,1=mild,2=moderate,3=severe). Endoscopic remission=SES-CD Total Score ≤4 \& at least 2-point reduction from baseline \& no subscore \>1.SES-CD evaluates 4 endoscopic variables in 5 bowel segments \& each of 20 individual variables scored 0-3: presence \& size of ulcers (none=0;diameter 0.1-0.5 cm=1;0.5-2 cm=2;\>2 cm=3);extent of ulcerated surface (none=0;\<10%=1;10% to 30%=2;\>30%=3);extent of affected surface (none=0;\<50%=1;50% to 75%=2;\>75%=3);presence \& type of narrowing (none=0;single,can be passed=1;multiple,can be passed=2;cannot be passed=3). Total is sum of all scores across all bowel segments. Scores range from 0 to 56;higher scores indicating more severe disease. No subscore \>1=no segmental subscore (sum of the 4 individual variable scores for each of the 5 bowel segments) \>1

Time frame:
Week 12 to Week 52
Reported as:
Mean · percentage of participants
Percentage of Adult Participants Achieving Clinical Response at Week 12 and Endoscopic Remission at Week 52 (Placebo and Mirikizumab)
percentage of participantsPlaceboMirikizumab
Percentage of Adult Participants Achieving Clinical Response at Week 12 and Endoscopic Remission at Week 52 (Placebo and Mirikizumab)2.0 (0.1 to 4.0)15.9 (12.9 to 18.9)
Statistical analysis
  • Placebo vs Mirikizumab · Cochran-Mantel-Haenszel · p = <0.000001 · Risk difference (rd): 13.8 · 95% CI 10.2 to 17.4
SecondaryPercentage of Adult Participants Achieving Clinical Response at Week 12 and Corticosteroid-free Clinical Remission at Week 52 (Placebo and Mirikizumab)

Clinical response by PRO defined as ≥30% decrease in SF and/or AP and neither score worse than baseline. SF (number of liquid or very soft stools) as per Bristol Stool Scale Category 6 or 7 and AP (4-point scale: 0=none, 1=mild, 2=moderate, 3=severe). Clinical remission defined as CDAI total score \<150. The CDAI is an 8- item disease activity measure comprised of a composite of 3 patient-reported items: AP (4-point scale: 0=none, 1=mild, 2=moderate, 3=severe); SF (number of liquid or very soft stools) as per Bristol Stool Scale Category 6 or 7; and general well-being (0=generally well, 1=slightly under par, 2=poor, 3=very poor, 4=terrible), and 5 physician-reported/laboratory items (physical signs and a laboratory parameter \[hematocrit\]). Total score range of 0 to 600 points. Corticosteroid-free clinical remission by CDAI is defined as achieving clinical remission by CDAI at Week 52 and being corticosteroid free from Week 40 to Week 52.

Time frame:
Week 12 to Week 52
Reported as:
Mean · percentage of participants
Percentage of Adult Participants Achieving Clinical Response at Week 12 and Corticosteroid-free Clinical Remission at Week 52 (Placebo and Mirikizumab)
percentage of participantsPlaceboMirikizumab
Percentage of Adult Participants Achieving Clinical Response at Week 12 and Corticosteroid-free Clinical Remission at Week 52 (Placebo and Mirikizumab)18.6 (13.2 to 24.0)43.7 (39.7 to 47.7)
Statistical analysis
  • Placebo vs Mirikizumab · Cochran-Mantel-Haenszel · p = <0.000001 · Risk difference (rd): 25.0 · 95% CI 18.2 to 31.8
SecondaryChange From Baseline in C-Reactive Protein (CRP) at Week 52 in Adult Participants (Placebo and Mirikizumab)

Change from baseline in CRP

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · milligram per liter (mg/L)
Change From Baseline in C-Reactive Protein (CRP) at Week 52 in Adult Participants (Placebo and Mirikizumab)
milligram per liter (mg/L)PlaceboMirikizumab
Change From Baseline in C-Reactive Protein (CRP) at Week 52 in Adult Participants (Placebo and Mirikizumab)-0.08 ± 0.087-0.93 ± 0.051
Statistical analysis
  • Placebo vs Mirikizumab · ANCOVA · p = <0.000001 · Lsmean difference (net): -0.85 · 95% CI -1.05 to -0.65
SecondaryChange From Baseline in Fecal Calprotectin at Week 52 in Adult Participants (Placebo and Mirikizumab)

Change from baseline in Fecal Calprotectin

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · micrograms per gram (μg/g)
Change From Baseline in Fecal Calprotectin at Week 52 in Adult Participants (Placebo and Mirikizumab)
micrograms per gram (μg/g)PlaceboMirikizumab
Change From Baseline in Fecal Calprotectin at Week 52 in Adult Participants (Placebo and Mirikizumab)-0.19 ± 0.117-1.41 ± 0.067
Statistical analysis
  • Placebo vs Mirikizumab · ANCOVA · p = <0.000001 · Lsmean difference (net): -1.22 · 95% CI -1.48 to -0.95
SecondaryPercentage of Adult Participants Achieving Clinical Response at Week 12 and Resolution of Baseline Extraintestinal Manifestations (EIMs) at Week 52 (Placebo and Mirikizumab)

Clinical response by PRO defined as ≥30% decrease in SF and/or AP and neither score worse than baseline. SF (number of liquid or very soft stools) as per Bristol Stool Scale Category 6 or 7 and AP (4-point scale: 0=none, 1=mild, 2=moderate, 3=severe).

Time frame:
Week 12 to Week 52
Reported as:
Number · percentage of participants
Percentage of Adult Participants Achieving Clinical Response at Week 12 and Resolution of Baseline Extraintestinal Manifestations (EIMs) at Week 52 (Placebo and Mirikizumab)
percentage of participantsPlaceboMirikizumab
Percentage of Adult Participants Achieving Clinical Response at Week 12 and Resolution of Baseline Extraintestinal Manifestations (EIMs) at Week 52 (Placebo and Mirikizumab)14.643.2
Statistical analysis
  • Placebo vs Mirikizumab · Cochran-Mantel-Haenszel · p = <0.0001
SecondaryPercentage of Adult Participants Achieving Clinical Response at Week 12 and ≥50% Reduction in Number of Draining Cutaneous Fistulae at Week 52 in Participants With Draining Cutaneous Fistulae at Baseline (Placebo and Mirikizumab)

Clinical response by PRO defined as ≥ 30% decrease in SF and/or AP and neither score worse than baseline. SF (number of liquid or very soft stools) as per Bristol Stool Scale Category 6 or 7 and AP (4-point scale: 0=none, 1=mild, 2=moderate, 3=severe).

Time frame:
Week 12 to Week 52
Reported as:
Mean · percentage of participants
Percentage of Adult Participants Achieving Clinical Response at Week 12 and ≥50% Reduction in Number of Draining Cutaneous Fistulae at Week 52 in Participants With Draining Cutaneous Fistulae at Baseline (Placebo and Mirikizumab)
percentage of participantsPlaceboMirikizumab
Percentage of Adult Participants Achieving Clinical Response at Week 12 and ≥50% Reduction in Number of Draining Cutaneous Fistulae at Week 52 in Participants With Draining Cutaneous Fistulae at Baseline (Placebo and Mirikizumab)16.7 (0.0 to 33.9)21.1 (8.1 to 34.0)
Statistical analysis
  • Placebo vs Mirikizumab · Cochran-Mantel-Haenszel · p = 0.732715 · Risk difference (rd): 4.1 · 95% CI -18.0 to 26.1
SecondaryChange From Baseline in Health Related Quality of Life at Week 52 in Adult Participants: Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score (Placebo and Mirikizumab)

The IBDQ is a 32-item patient completed questionnaire that measures 4 aspects of patients' lives: symptoms directly related to the primary bowel disturbance, systemic symptoms, emotional function, and social function. Responses are graded on a 7-point Likert scale in which 7 denotes "not a problem at all" and 1 denotes "a very severe problem." IBDQ total score is calculated as the sum of all questions. Scores range from 32 to 224; a higher score indicates a better quality of life.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · score on a scale
Change From Baseline in Health Related Quality of Life at Week 52 in Adult Participants: Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score (Placebo and Mirikizumab)
score on a scalePlaceboMirikizumab
Change From Baseline in Health Related Quality of Life at Week 52 in Adult Participants: Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score (Placebo and Mirikizumab)15.9 ± 2.31643.82 ± 1.365
Statistical analysis
  • Placebo vs Mirikizumab · ANCOVA · p = <0.000001 · Lsmean difference (net): 27.92 · 95% CI 22.67 to 33.18
SecondaryAdult Population Pharmacokinetics (PopPK): Area Under the Concentration Time Curve (AUC) of Mirikizumab

PopPK: AUC of Mirikizumab

Time frame:
900 mg Mirikizumab: Week 4: Predose; Week 4, Day 1: Postdose; Week 8, 12: Predose 300 mg Mirikizumab: Week 16, 24, 36: Predose; Week 52
Reported as:
Geometric mean · micrograms*day per milliliter(ug*day/mL)
Adult Population Pharmacokinetics (PopPK): Area Under the Concentration Time Curve (AUC) of Mirikizumab
micrograms*day per milliliter(ug*day/mL)900 mg Mirikizumab IV Q4W300 mg Mirikizumab SC Q4W
Adult Population Pharmacokinetics (PopPK): Area Under the Concentration Time Curve (AUC) of Mirikizumab1820 ± 38.1220 ± 55.9
Post-hocPercentage of Adult Participants Achieving Alternate Endoscopic Remission at Week 12 (Placebo and Mirikizumab)

Alternate endoscopic remission is defined as SES-CD Total Score ≤4 and at least a 2-point reduction from baseline and no subscore \>1. SES-CD evaluates 4 endoscopic variables in 5 bowel segments and each of the 20 individual variables is scored from 0-3: presence \& size of ulcers (none = 0; diameter 0.1-0.5 cm = 1; 0.5-2 cm = 2; \>2 cm = 3); extent of ulcerated surface (none = 0; \<10% = 1; 10% to 30% = 2; \>30% = 3); extent of affected surface (none = 0; \<50% = 1; 50% to 75% = 2; \>75% = 3); presence \& type of narrowing (none = 0; single, can be passed = 1; multiple, can be passed = 2; cannot be passed =3). Total is sum of all scores across all bowel segments. Scores range from 0 to 56, with higher scores indicating more severe disease. No subscore \>1 is defined as no subscore \>1 in any of the 20 individual variables.

Time frame:
Week 12
Reported as:
Mean · percentage of participants
Percentage of Adult Participants Achieving Alternate Endoscopic Remission at Week 12 (Placebo and Mirikizumab)
percentage of participantsPlaceboMirikizumab
Percentage of Adult Participants Achieving Alternate Endoscopic Remission at Week 12 (Placebo and Mirikizumab)7.0 (1.9 to 12.1)17.6 (13.2 to 22.1)
Statistical analysis
  • Placebo vs Mirikizumab · Cochran-Mantel-Haenszel · p = 0.000213 · Risk difference (rd): 10.6 · 99.5% CI 4.1 to 17.2
Post-hocPercentage of Adult Participants Achieving Clinical Response at Week 12 and Alternate Endoscopic Remission at Week 52 (Placebo and Mirikizumab)

Clinical Response by PRO defined as ≥30% decrease in SF and/or AP \& neither score worse than baseline. SF (number of liquid or very soft stools) per Bristol Stool Scale Category 6 or 7 \& AP (4-point scale:0=none,1=mild,2=moderate,3=severe). Alternate endoscopic remission defined as SES-CD Total Score ≤4 \& at least 2-point reduction from baseline \& no subscore \>1.SES-CD evaluates 4 endoscopic variables in 5 bowel segments \& each of 20 individual variables scored 0-3: presence \& size of ulcers (none=0;diameter 0.1-0.5 cm=1;0.5-2 cm=2;\>2 cm=3); extent of ulcerated surface (none=0;\<10%=1;10% to 30%=2;\>30%=3);extent of affected surface (none=0;\<50%=1;50% to 75%=2;\>75%=3); presence \& type of narrowing (none=0;single,can be passed=1;multiple,can be passed=2;cannot be passed=3). Total is sum of all scores across all bowel segments. Scores range from 0 to 56, with higher scores indicating more severe disease. No subscore \>1 is defined as no subscore \>1 in any of the 20 individual variables.

Time frame:
Week 12 to Week 52
Reported as:
Mean · percentage of participants
Percentage of Adult Participants Achieving Clinical Response at Week 12 and Alternate Endoscopic Remission at Week 52 (Placebo and Mirikizumab)
percentage of participantsPlaceboMirikizumab
Percentage of Adult Participants Achieving Clinical Response at Week 12 and Alternate Endoscopic Remission at Week 52 (Placebo and Mirikizumab)4.0 (0.1 to 7.9)23.5 (18.5 to 28.4)
Statistical analysis
  • Placebo vs Mirikizumab · Cochran-Mantel-Haenszel · p = <0.000001 · Risk difference (rd): 19.4 · 99.5% CI 13.1 to 25.7

Adverse events

Collected over Baseline up to follow up (up to 68 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo1/211 (0.5%)37/211 (17.5%)66/211 (31.3%)
Placebo Non-Responders1/85 (1.2%)7/85 (8.2%)27/85 (31.8%)
Mirikizumab0/630 (0%)65/630 (10.3%)300/630 (47.6%)
Ustekinumab1/309 (0.3%)35/309 (11.3%)131/309 (42.4%)
Mirikizumab (Adolescents)0/6 (0%)0/6 (0%)5/6 (83.3%)
Most frequent serious events
Showing 10 of 94
Most frequent serious events
EventPlaceboPlacebo Non-RespondersMirikizumabUstekinumabMirikizumab (Adolescents)
Crohn's diseaseGastrointestinal disorders14/2112/8512/63011/3090/6
Anal fistulaGastrointestinal disorders4/2110/850/6301/3090/6
IleusGastrointestinal disorders0/2111/852/6301/3090/6
Intestinal obstructionGastrointestinal disorders1/2111/853/6300/3090/6
Intestinal perforationGastrointestinal disorders0/2111/850/6300/3090/6
Procedural intestinal perforationInjury, poisoning and procedural complications0/2111/850/6300/3090/6
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders0/2111/850/6300/3090/6
SalpingitisInfections and infestations1/860/370/2740/1610/3
Abdominal painGastrointestinal disorders2/2110/852/6300/3090/6
Bile duct stoneHepatobiliary disorders2/2110/850/6300/3090/6
Most frequent other events
Showing 10 of 18
Most frequent other events
EventPlaceboPlacebo Non-RespondersMirikizumabUstekinumabMirikizumab (Adolescents)
Crohn's diseaseGastrointestinal disorders21/2114/8517/63014/3091/6
DiarrhoeaGastrointestinal disorders8/2111/8533/63012/3091/6
Gastrooesophageal reflux diseaseGastrointestinal disorders1/2110/8511/6302/3091/6
VomitingGastrointestinal disorders2/2112/8524/6306/3091/6
PyrexiaGeneral disorders5/2112/8527/6309/3091/6
HypersensitivityImmune system disorders1/2110/853/6302/3091/6
Covid-19Infections and infestations21/2116/85103/63046/3091/6
Epstein-barr virus infectionInfections and infestations0/2110/850/6300/3091/6
GastroenteritisInfections and infestations5/2110/8515/6308/3091/6
PharyngotonsillitisInfections and infestations0/2110/850/6300/3091/6

Baseline characteristics

Adults: All randomized participants; Adolescents: All participants who received at least one dose of study drug.

Age, Categorical
Age, Categorical(Participants)PlaceboMirikizumabUstekinumabMirikizumab (Adolescent)Total
<=18 years4116627
Between 18 and 65 years20559829501098
>=65 years3228033
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboMirikizumabUstekinumabMirikizumab (Adolescent)Total
Female872741613525
Male1253571483633
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboMirikizumabUstekinumabMirikizumab (Adolescent)Total
Hispanic or Latino486018
Not Hispanic or Latino165825099
Unknown or Not Reported19256527861041
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboMirikizumabUstekinumabMirikizumab (Adolescent)Total
American Indian or Alaska Native22206
Asian44158782282
Native Hawaiian or Other Pacific Islander00000
Black or African American5128025
White1554482194826
More than one race03104
Unknown or Not Reported681015
Region of Enrollment
Region of Enrollment(Participants)PlaceboMirikizumabUstekinumabMirikizumab (Adolescent)Total
United States2066310117
Czechia112917057
Russia224420086
Austria073010
Latvia01203
Netherlands12104
South Korea74011260
China3190430164
Brazil112918058
Poland2883473161
Slovakia2107019
France33107
Lithuania13105
Serbia876021
Croatia16007
Argentina02002
Romania1102013
Hungary51910034
Japan41113028
Ukraine124333088
United Kingdom04105
Switzerland13307
India21310025
Spain13004
Canada8198035
Turkey6287041
Belgium25209
Denmark02002
Italy34018
Mexico14207
Israel492015
Australia8100018
Germany8228038
08

Study locations

580 sites
  • University of Alabama-The Kirklin Clinic
    Birmingham, Alabama 35233, United States
  • Digestive Health Specialists
    Dothan, Alabama 36301, United States
  • Lakeview Clinical Research
    Guntersville, Alabama 35976, United States
  • Care Access Research - Tuscaloosa
    Tuscaloosa, Alabama 35406, United States
  • Research Solutions of Arizona
    Litchfield Park, Arizona 85340, United States
  • Central Arizona Medical Associates, PC
    Mesa, Arizona 85206, United States
  • Arizona Arthritis & Rheumatology Research, PLLC
    Phoenix, Arizona 85037, United States
  • Reliance Research
    Scottsdale, Arizona 85260, United States
  • Synexus Site Network
    Tempe, Arizona 85282, United States
  • inSite Digestive Health Care
    Arcadia, California 91006, United States
  • B G Clinical Research, Inc.
    Encinitas, California 92024, United States
  • Care Access - Gilroy
    Gilroy, California 95020, United States
  • Newport Huntington Med Grp
    Huntington Beach, California 92648, United States
  • Om Research, LLC
    Lancaster, California 93534, United States
  • GastroIntestinal Biosciences Clinical Trials
    Los Angeles, California 90067, United States
  • California Medical Research Associates
    Northridge, California 91324, United States
  • University of California Irvine
    Orange, California 92868, United States
  • inSite Digestive Health Care
    Pasadena, California 91105, United States
  • Care Access Research - San Jose
    San Jose, California 95124, United States
  • Wolverine Clinical Trials, LLC
    Santa Ana, California 92705, United States
  • Fomat Medical Research, Inc.
    Thousand Oaks, California 91360, United States
  • Connecticut Gastroenterology
    Manchester, Connecticut 06040, United States
  • IMR of South Florida
    Aventura, Florida 33180, United States
  • Gastroenterology Consultants of Clearwater
    Clearwater, Florida 33756, United States
  • West Central Gastroenterology d/b/a Gastro Florida
    Clearwater, Florida 33761, United States
  • Inpatient Research Clinic
    Hialeah, Florida 33013, United States
  • Doral Medical Research
    Hialeah, Florida 33016, United States
  • C2 Research Center, LLC
    Jacksonville, Florida 32204, United States
  • I.H.S. Health, LLC
    Kissimmee, Florida 34741, United States
  • Central Florida Gastro Research
    Kissimmee, Florida 34744, United States
  • Florida Research Institute
    Lakewood Ranch, Florida 34211, United States
  • Wellness Clinical Research
    Lehigh Acres, Florida 33936, United States
  • Goji Group - Research Trials Group
    Miami Lakes, Florida 33016, United States
  • Wellness Clinical Research
    Miami Lakes, Florida 33016, United States
  • Columbus Clinical Services, LLC
    Miami, Florida 33125, United States
  • Infinite Clinical Research
    Miami, Florida 33133, United States
  • Nickalus Children's Hospital Research Institute
    Miami, Florida 33155, United States
  • Research Associates of South Florida, LLC
    Miami, Florida 33156, United States
  • SaludMax Medical Corp
    Miami, Florida 33165, United States
  • Ezy Medical Research
    Miami, Florida 33175, United States
  • Coral Research Clinic Corp
    Miami, Florida 33186, United States
  • Center for Interventional Endoscopy
    Orlando, Florida 32803, United States
  • Endoscopic Research Inc
    Orlando, Florida 32803, United States
  • Orlando Health, Inc
    Orlando, Florida 32806, United States
  • Clintheory Healthcare
    Orlando, Florida 32819, United States
  • Care Access Research - Orlando
    Orlando, Florida 32825, United States
  • Digestive and Liver Center of Florida
    Orlando, Florida 32825, United States
  • Gastroenterology Associates of Pensacola, PA
    Pensacola, Florida 32503, United States
  • Synexus Clinical Research US, Inc.
    Pinellas Park, Florida 33781, United States
  • USPA Advance Concept Medical Research Group LLC.
    South Miami, Florida 33143, United States
  • Precision Clinical Research
    Sunrise, Florida 33351, United States
  • Advanced Research
    Tamarac, Florida 33321, United States
  • University of South Florida
    Tampa, Florida 33612, United States
  • Alliance Clinical Research, LLC
    Tampa, Florida 33615, United States
  • Grady Memorial Hospital
    Atlanta, Georgia 30303, United States
  • Digestive Healthcare of Georgia
    Atlanta, Georgia 30309, United States
  • Columbus Regional Research Institute
    Columbus, Georgia 31904, United States
  • Gastrointestinal Specialists of Georgia
    Marietta, Georgia 30060, United States
  • Grand Teton Research Group
    Idaho Falls, Idaho 83404, United States
  • Eagle Clinical Research
    Chicago, Illinois 60621, United States
  • Qualmedica Research, LLC
    Evansville, Indiana 47715, United States
  • Indiana University Health
    Indianapolis, Indiana 46202, United States
  • Care Access Research - Terre Haute
    Terre Haute, Indiana 47802, United States
  • University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
  • Robley Rex VA Medical Center
    Louisville, Kentucky 40206, United States
  • CroNola LLC
    Houma, Louisiana 70360, United States
  • Delta Research Partners LLC
    Monroe, Louisiana 71201, United States
  • Nola Research Works, LLC
    New Orleans, Louisiana 70125, United States
  • Louisiana Clinical Research, LLC
    Shreveport, Louisiana 71105, United States
  • MGG Group, Inc.., Co., Chevy Chase Clinical Research
    Chevy Chase, Maryland 20815, United States
  • Woodholme Gastroenterology Associates - Glen Burnie
    Glen Burnie, Maryland 21061, United States
  • Capital Digestive Care
    Rockville, Maryland 20850, United States
  • Tufts Medical Center
    Boston, Massachusetts 02111, United States
  • Clinical Research Institute of Michigan, LLC
    Chesterfield, Michigan 48047, United States
  • Henry Ford Health System
    Detroit, Michigan 48202, United States
  • Revive Research Institute
    Farmington Hills, Michigan 48334, United States
  • Infusion Associates
    Grand Rapids, Michigan 49525, United States
  • MNGI Digestive Health, P.A.
    Plymouth, Minnesota 55446, United States
  • Gastrointestinal Associates
    Flowood, Mississippi 39232, United States
  • University of Mississippi School of Medicine
    Jackson, Mississippi 39216-4500, United States
  • Southern Therapy and Advanced Research (STAR) LLC
    Jackson, Mississippi 39216, United States
  • Digestive Health Specialists
    Tupelo, Mississippi 38801, United States
  • BVL Research
    Liberty, Missouri 64068, United States
  • Advanced Biomedical Research of America - South Eastern Avenue
    Las Vegas, Nevada 89123, United States
  • Care Access - Las Vegas
    Las Vegas, Nevada 89148, United States
  • Lovelace Scientific Resources - Albuquerque
    Albuquerque, New Mexico 87108, United States
  • NYU Langone Long Island Clinical Research Associates
    Lake Success, New York 11042, United States
  • Care Access Research - Yonkers
    Yonkers, New York 10701, United States
  • Unc Hospitals
    Chapel Hill, North Carolina 27599, United States
  • Javara
    Charlotte, North Carolina 28210, United States
  • Medication Management
    Greensboro, North Carolina 27405, United States
  • Peters Medical Research
    High Point, North Carolina 27262, United States
  • Care Access Research-Kinston
    Kinston, North Carolina 28501, United States
  • Care Access Research-Lumberton
    Lumberton, North Carolina 28358, United States
  • Gastroenterology Associates of the Piedmont
    Winston-Salem, North Carolina 27103, United States
  • University Hospitals Cleveland Medical Center
    Cleveland, Ohio 44106, United States
  • Ohio State University Hospital
    Columbus, Ohio 43210, United States
  • Ohio Gastroenterology Group Inc.
    Dublin, Ohio 43016, United States
  • Northshore Gastroenterology Research, LLC
    Westlake, Ohio 44145, United States
  • University of Oklahoma Health Sciences Center
    Oklahoma City, Oklahoma 73104, United States

Showing the first 100 of 580 sites across 34 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2019 to primary completion in Aug 2023, 49 months.

Results were first posted in Dec 2024, 1 year 4 months after primary completion.

Of 70 industry-sponsored phase 3 interventional studies under Crohn Disease, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 69. This study's 49 months is close to that.

Counting every sponsor, half of 88 studies reached it within 49 months; a quarter within 36 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 23, 2019
First posted
Apr 24, 2019
StartActual
Jul 23, 2019
Primary completionActual
Aug 23, 2023
CompletionActual
Oct 2, 2023
Results first posted
Dec 27, 2024
Last update
Dec 27, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 27, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03926130
Responsible party
Sponsor
First posted
Apr 24, 2019
Start date
Jul 23, 2019
Primary completion
Aug 23, 2023
Completion
Oct 2, 2023
Results posted
Dec 27, 2024
Last update
Dec 27, 2024

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM -5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mirikizumab

Start the discussion